Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Corcept Therapeutics Incorporated CORT

Healthcare  —  Biotechnology
116.10 (2.41) (2.03%) as of 25 Sep
Market cap
$12.9B
P/E
223×
Revenue Champion (10y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Corcept Therapeutics Incorporated (CORT) Business Profile

Updated before January 2025

Company Overview

Corcept Therapeutics Incorporated (CORT) is a publicly traded pharmaceutical company headquartered in Menlo Park, California. Founded in 1998 by Dr. Joseph K. Belanoff, Dr. Alan F. Schatzberg, and others, the company focuses on the discovery, development, and commercialization of medications that modulate the effects of cortisol, a hormone involved in various physiological processes. Dr. Joseph K. Belanoff serves as the Chief Executive Officer, and the company is governed by a team of experienced executives and board members with extensive expertise in the pharmaceutical and biotechnology industries.

Corcept Therapeutics is best known for its work in endocrinology, psychiatry, and oncology, with a particular emphasis on addressing unmet medical needs. The company’s flagship product, Korlym® (mifepristone), was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of hyperglycemia secondary to Cushing’s syndrome in adults who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

Core Business Segments

Endocrinology

Corcept Therapeutics’ primary focus is on the treatment of endocrine disorders, particularly those related to cortisol dysregulation. The company’s flagship product, Korlym®, is a cortisol receptor antagonist used to treat patients with Cushing’s syndrome. This rare and debilitating condition is caused by prolonged exposure to high levels of cortisol, leading to symptoms such as weight gain, high blood pressure, and diabetes. Korlym® helps mitigate these symptoms by blocking cortisol’s effects on its receptors.

Oncology

In addition to its work in endocrinology, Corcept is actively exploring the role of cortisol modulation in oncology. The company is investigating the potential of its proprietary selective cortisol modulators to enhance the efficacy of existing cancer therapies. These efforts are focused on improving outcomes for patients with solid tumors, including ovarian, pancreatic, and prostate cancers.

Psychiatry

Corcept has also conducted research into the use of cortisol modulators for psychiatric conditions such as major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). While these programs are not as advanced as the company’s work in endocrinology and oncology, they represent an important area of potential growth.

Business Model

Corcept Therapeutics operates on a business model centered around the development and commercialization of proprietary medications that address unmet medical needs. The company generates revenue primarily through the sale of Korlym®, which is marketed directly to healthcare providers and patients in the United States. Corcept also invests heavily in research and development (R&D) to expand its pipeline of selective cortisol modulators.

The company’s R&D efforts are supported by a robust intellectual property portfolio, which includes patents covering the composition, use, and manufacturing of its products. This ensures a competitive advantage and provides a foundation for long-term growth. Corcept also collaborates with academic institutions and other organizations to advance its scientific understanding and identify new therapeutic opportunities.

Strategic Direction

Corcept Therapeutics is committed to expanding its product portfolio and addressing additional medical conditions associated with cortisol dysregulation. The company’s strategic priorities include:

  • Pipeline Expansion: Corcept is actively developing new selective cortisol modulators for a range of indications, including oncology and metabolic disorders. The company is conducting multiple clinical trials to evaluate the safety and efficacy of these compounds.
  • Geographic Expansion: While Korlym® is currently approved only in the United States, Corcept is exploring opportunities to expand its presence in international markets.
  • Sustainability Goals: Corcept is dedicated to operating in an environmentally and socially responsible manner. The company aims to minimize its environmental footprint and contribute positively to the communities it serves.
  • Partnerships and Collaborations: Corcept seeks to establish strategic partnerships with other pharmaceutical companies, academic institutions, and research organizations to accelerate the development of innovative therapies.

Competitive Landscape

Corcept Therapeutics operates in a competitive pharmaceutical market, facing challenges from both established companies and emerging players. Key competitors include:

  • HRA Pharma: A global pharmaceutical company that markets Metopirone®, a diagnostic agent used to assess adrenal function.
  • Strongbridge Biopharma: A biopharmaceutical company focused on rare endocrine diseases, including Cushing’s syndrome.
  • Novartis: A multinational pharmaceutical company that markets Signifor® (pasireotide), a treatment for Cushing’s disease.
  • Generic Drug Manufacturers: Korlym® faces potential competition from generic versions of mifepristone, which could impact Corcept’s market share and pricing power.

Risk Factors

Corcept Therapeutics faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the sales of Korlym®, which accounts for the majority of its revenue. Any decline in demand for this product could have a significant impact on Corcept’s financial results.
  • Regulatory Risks: The pharmaceutical industry is highly regulated, and any delays or setbacks in obtaining regulatory approvals for new products could hinder Corcept’s growth.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its products. Any disruptions in the supply chain could affect product availability and revenue.
  • Patent Expiry: The expiration of key patents could expose Corcept to generic competition, potentially eroding its market share and profitability.
  • Litigation Risks: Corcept has faced legal challenges related to its intellectual property and business practices, which could result in financial liabilities and reputational damage.

Recent Developments

Corcept Therapeutics has made significant progress in advancing its pipeline and strengthening its market position. Recent developments include:

  • Clinical Trials: The company is conducting multiple Phase 2 and Phase 3 clinical trials to evaluate the efficacy of its selective cortisol modulators in oncology and other indications.
  • Patent Litigation: Corcept has successfully defended its intellectual property in several legal disputes, ensuring continued market exclusivity for Korlym®.
  • Corporate Strategy: The company has announced plans to expand its R&D capabilities and explore new therapeutic areas, including metabolic disorders and neurodegenerative diseases.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of resilient supply chains and accelerated the adoption of digital technologies in healthcare, both of which have influenced Corcept’s operational strategies.

Investment Considerations

Strengths

  • Market Leadership: Corcept is a leader in the field of cortisol modulation, with a proven track record of developing innovative therapies.
  • Robust Pipeline: The company has a strong pipeline of selective cortisol modulators, which could drive future growth.
  • Intellectual Property: Corcept’s extensive patent portfolio provides a competitive advantage and protects its market position.
  • Experienced Leadership: The company is led by a team of seasoned executives with deep expertise in the pharmaceutical industry.

Risks

  • Revenue Concentration: Corcept’s reliance on Korlym® for the majority of its revenue poses a significant risk.
  • Regulatory Challenges: Delays or setbacks in obtaining regulatory approvals could impact the company’s growth prospects.
  • Competition: The pharmaceutical market is highly competitive, and Corcept faces challenges from both established players and new entrants.
  • Litigation Risks: Ongoing legal disputes could result in financial liabilities and reputational damage.

Conclusion

Corcept Therapeutics Incorporated is a pioneering pharmaceutical company with a strong focus on cortisol modulation. The company’s flagship product, Korlym®, has established it as a leader in the treatment of Cushing’s syndrome, and its robust pipeline of selective cortisol modulators holds promise for addressing additional medical conditions. While Corcept faces challenges such as revenue concentration and regulatory risks, its market leadership, intellectual property portfolio, and experienced leadership team position it well for future growth. As the company continues to expand its product portfolio and explore new therapeutic areas, it remains a compelling investment opportunity for those seeking exposure to the pharmaceutical sector.